Annexon Highlights Strategic Focus to Advance Four Flagship
Mid-stage and Pivotal Trials of ANX005, ANX007 and ANX1502 Poised to Achieve Numerous Catalysts in Multiple Disease Indications Well-Capitalized with...
Source: globenewswire.com
Stay updated with breaking news from Multiple Disease. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Mid-stage and Pivotal Trials of ANX005, ANX007 and ANX1502 Poised to Achieve Numerous Catalysts in Multiple Disease Indications Well-Capitalized with...